Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Innate Pharma S.A.NASDAQ: IPHA

Net Debt · Q4 FY2025 · quarter ended Dec 2025

Net debt remains negative

Q4 FY2025 net debt was -€5.52M, compared with -€35.4M a year earlier.

Context

  • Net debt amounted to 8.8% of total assets at the end of Q4 FY2025, down 23.1 pp from a year earlier.
  • Net debt grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +84.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€5.52M— QoQ
Last fiscal yearDec 2025
-€5.52M+84.4% YoY
Year agoDec 2024
-€35.4M+84.4% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+84.4%——
1 year+84.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

EUR · from the balance sheet

Latest · FY2025
(5.52M) EUR
Year-over-year change
+84.4%

Net Debt vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +84.4% is the 3rd highest of 9, against a peer median of +17.7%.
  • Net debt amounts to 8.8% of total assets for IPHA, versus a peer median of 16.6%.
IPHA Competitors
Net Debt for IPHA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MISTMilestone Pharmaceuticals Inc.Mar 2026$66.01M USD+528.6%—34.1%
ELTXElicio Therapeutics, Inc.Mar 2026-$608K USD+95.2%—2.7%
IPHAInnate Pharma S.A.Dec 2025-€5.52M EUR+84.4%—8.8%
RANIRani Therapeutics Holdings, Inc.Mar 2026-$5.7M USD-136.7%—11.0%
CRDFCardiff Oncology, Inc.Mar 2026-$7.9M USD+65.3%—16.1%
CGENCompugen Ltd.Mar 2026-$9.5M USD+19.5%—6.5%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026-$24.84M USD-54.8%—17.2%
NVCTNuvectis Pharma, Inc.Mar 2026-$25.13M USD+15.9%—98.9%
MOLNMolecular Partners AGMar 2026-CHF 75.2M CHF+5.1%—86.0%
Peer median (excluding IPHA) —+17.7%—16.6%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents103.76M84.23M70.61M66.4M28.08M
Short-term Investments16.08M17.26M21.85M14.37M6.22M
Net Receivables1.66M3.14M46.49M1.64M7.61M
Inventory00000
Other Current Assets11.81M27.88M00(4.28K)
Total Current Assets138.26M139.83M148.01M85.74M46.69M
Property, Plant & Equipment (Net)10.17M8.54M6.32M5.13M4.35M
Goodwill2K(41M)000
Intangible Assets44.19M42.55M416K00
Long-term Investments39.88M35.12M9.8M10.28M10.7M
Tax Assets5.03M8.57M9.01M00
Other Non-current Assets29.97M14.25M1.64M9.9M946.6K
Total Non-current Assets129.24M68.03M27.18M25.32M16M
Total Assets267.5M207.86M175.19M111.06M62.69M
Account Payables14.73M13.66M8.56M7.92M15.04M
Short-term Debt29.94M1.26M8.45M8.44M8.52M
Tax Payables7.46M5.98M7.02M6.96M0
Deferred Revenue12.5M6.56M5.87M616K2.82M
Other Current Liabilities21.91M19.02M7.82M7.65M9.97M
Total Current Liabilities79.89M41.34M39.64M32.98M36.63M
Long-term Debt11.49M38.93M30.61M22.18M13.67M
Deferred Tax Liabilities5.03M8.57M9.01M00
Deferred Revenue (Non-current)25.41M7.92M4.62M2.83M0
Other Non-current Liabilities36.23M55.74M39.07M44.13M33.99M
Total Non-current Liabilities80.17M112.37M83.65M69.24M47.75M
Total Liabilities160.06M153.71M132.29M102.23M84.39M
Common Stock3.98M4.01M4.04M4.19M4.69M
Retained Earnings(272.21M)(330.32M)(336.89M)(386.36M)(435.36M)
Accumulated OCI456K819K495K27K1.12M
Other Stockholders Equity(1K)0000
Minority Interest00000
Total Equity107.44M54.15M51.9M8.83M(21.69M)
Total Debt44.25M42.25M39.89M31M22.56M
Net Debt(59.51M)(41.97M)(30.71M)(35.4M)(5.52M)

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.